Skip to main content
. 2021 Jun 8;6(11):e147929. doi: 10.1172/jci.insight.147929

Figure 1. Intraoperative identification and sampling of MRD in ovarian cancer patients.

Figure 1

(A) Diagram shows the sampling technique used in the OXO-PCR study. All 17 patients had paired biopsies collected at the time of diagnostic laparoscopy (pre-chemo) and during the IDS that followed at least 3 cycles of NACT (post-chemo). (B) Representative images showing the tumor burden in poor and exceptional responders before and after treatment. The MRD cancer islets are not visible during the IDS and can only be detected with a hematoxylin-and-eosin staining of the biopsy. (C) Diagram shows the RNA-Seq pipeline. Each biopsy was cryosectioned, stained, and assessed by a gynecological oncology pathologist to confirm presence of cancer cells; RNA-Seq libraries were prepared from both bulk and laser capture microdissected material, followed by differential expression analysis across time points and response groups.